These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1445703)

  • 1. Factors to be considered in the evaluation of bioavailability and bioequivalence of topical formulations.
    Borsadia S; Ghanem AH; Seta Y; Higuchi WI; Flynn GL; Behl CR; Shah VP
    Skin Pharmacol; 1992; 5(3):129-45. PubMed ID: 1445703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stratum Corneum Sampling to Assess Bioequivalence between Topical Acyclovir Products.
    Pensado A; Chiu WS; Cordery SF; Rantou E; Bunge AL; Delgado-Charro MB; Guy RH
    Pharm Res; 2019 Nov; 36(12):180. PubMed ID: 31728737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Approach for the Bioequivalence Assessment of Topical Cream Formulations: Model-Based Analysis of Tape Stripping Data Correctly Concludes BE and BIE.
    Ozdin D; Kanfer I; Ducharme MP
    Pharm Res; 2020 Jan; 37(2):20. PubMed ID: 31897770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal Drug.
    Leal LB; Cordery SF; Delgado-Charro MB; Bunge AL; Guy RH
    Pharm Res; 2017 Apr; 34(4):730-737. PubMed ID: 28097506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in methodologies for evaluating bioequivalence of topical formulations.
    Shah VP
    Am J Clin Dermatol; 2001; 2(5):275-80. PubMed ID: 11721645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical bioavailability of diclofenac from locally-acting, dermatological formulations.
    Cordery SF; Pensado A; Chiu WS; Shehab MZ; Bunge AL; Delgado-Charro MB; Guy RH
    Int J Pharm; 2017 Aug; 529(1-2):55-64. PubMed ID: 28636892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New guidelines for the assessment of bioavailability and bioequivalence].
    Blume H; Schug B; Tautz J; Erb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):548-55. PubMed ID: 15887065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and bioequivalence of topical glucocorticoids.
    Wiedersberg S; Leopold CS; Guy RH
    Eur J Pharm Biopharm; 2008 Mar; 68(3):453-66. PubMed ID: 17826047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence.
    Zha J; Endrenyi L
    J Biopharm Stat; 1997 Mar; 7(1):191-204. PubMed ID: 9056598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.
    Schwarb FP; Imanidis G; Smith EW; Haigh JM; Surber C
    Pharm Res; 1999 Jun; 16(6):909-15. PubMed ID: 10397613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin as an active metabolizing barrier I: Theoretical analysis of topical bioavailability.
    Ando HY; Ho NF; Higuchi WI
    J Pharm Sci; 1977 Nov; 66(11):1525-8. PubMed ID: 915724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing metrics for the assessment of bioequivalence between topical drug products.
    N'Dri-Stempfer B; Navidi WC; Guy RH; Bunge AL
    Pharm Res; 2008 Jul; 25(7):1621-30. PubMed ID: 18449629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement, analysis and prediction of topical UV filter bioavailability.
    Roussel L; Gilbert E; Salmon D; Serre C; Gabard B; Haftek M; Maibach HI; Pirot F
    Int J Pharm; 2015 Jan; 478(2):804-10. PubMed ID: 25526673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
    Wiedersberg S; Naik A; Leopold CS; Guy RH
    Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical bio(in)equivalence of metronidazole formulations in vivo.
    de Araujo TP; Fittipaldi IM; Bedor DCG; Duarte ML; Cordery SF; Guy RH; Delgado-Charro MB; de Santana DP; Leal LB
    Int J Pharm; 2018 Apr; 541(1-2):167-172. PubMed ID: 29462685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Principles and criteria in the development and optimization of topical therapeutic products.
    Shah VP; Behl CR; Flynn GL; Higuchi WI; Schaefer H
    J Pharm Sci; 1992 Oct; 81(10):1051-4. PubMed ID: 1432620
    [No Abstract]   [Full Text] [Related]  

  • 20. Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug.
    Sperry DC; Thomas SJ; Lobo E
    Mol Pharm; 2010 Oct; 7(5):1450-7. PubMed ID: 20704266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.